Patents by Inventor Licheng Shi

Licheng Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20250129172
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: October 2, 2024
    Publication date: April 24, 2025
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Human CGRP receptor binding proteins
    Patent number: 12134652
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: November 5, 2024
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Human CGRP receptor binding proteins
    Patent number: 12122841
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: October 22, 2024
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20210179723
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, Jr., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20210179722
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 3, 2020
    Publication date: June 17, 2021
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20180142029
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: November 28, 2017
    Publication date: May 24, 2018
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Human CGRP receptor binding proteins
    Patent number: 9862771
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: January 9, 2018
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • HUMAN CGRP RECEPTOR BINDING PROTEINS
    Publication number: 20150376286
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: June 26, 2015
    Publication date: December 31, 2015
    Applicant: AMGEN INC.
    Inventors: Thomas C. BOONE, David W. BRANKOW, Colin V. GEGG, JR., Shaw-Fen Sylvia HU, Chadwick T. KING, Hsieng Sen LU, Licheng SHI, Cen XU
  • Human CGRP receptor binding proteins
    Patent number: 9102731
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: August 11, 2015
    Assignee: AMGEN INC.
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, Jr., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Human CGRP Receptor Binding Proteins
    Publication number: 20130071410
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related, disorders including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, JR., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Human CGRP Receptor Binding Proteins
    Publication number: 20100172895
    Abstract: Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of CGRP R to CGRP, and are useful in a number of CGRP R related disorders, including the treatment and/or prevention of migraine headaches.
    Type: Application
    Filed: December 18, 2009
    Publication date: July 8, 2010
    Inventors: Thomas C. Boone, David W. Brankow, Colin V. Gegg, JR., Shaw-Fen Sylvia Hu, Chadwick T. King, Hsieng Sen Lu, Licheng Shi, Cen Xu
  • Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
    Patent number: 6713268
    Abstract: Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: March 30, 2004
    Assignee: Allergan, Inc.
    Inventors: David F. Woodward, Licheng Shi, Achim H-P Krauss, Clayton S. Spada, Sheila Mac Neil, Linda C. Smith-Thomas
  • Glaucoma treatments with reduced hyperpigmentation
    Publication number: 20030018078
    Abstract: Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.
    Type: Application
    Filed: June 26, 2001
    Publication date: January 23, 2003
    Applicant: Allergan Sales, Inc.
    Inventors: David F. Woodward, Licheng Shi, Achim H-P Krauss, Clayton S. Spada, Sheila Mac Neil, Linda C. Smith-Thomas